L’Oréal
This article was originally published in The Rose Sheet
Executive Summary
Acquisition of tissue engineering company SkinEthic by French beauty marketer's Episkin subsidiary, which is dedicated to development of reconstructed skin, is aimed at helping L'Oréal enhance development of in vitro test methods, firm says in Feb. 28 release. SkinEthic is an "important worldwide player in the production and commercialization of human epidermal and epithelial tissues," including epidermis, dermis and corneal tissues, L'Oréal notes. "The acquisition of SkinEthic allows us to respond to the needs of the entire industry and more specifically in the area of alternative approaches to animal testing," firm adds. Marketing of most cosmetic products tested on animals is prohibited under 7th Amendment to EU's Cosmetics Directive beginning in 2009...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.